| 摘要 |
The present invention provides for fusion proteins that act as targeted drug carries. The proteins are derived from molecules that possess natural drug-binding capabilities that are further engineered to target specific cell types, and optionally to have altered/improved drug binding characteristics. These fusion proteins are useful in, for example, delivery of chemotherapeutic compounds to cancer cells.
|
